List of Excipients in Branded Drug THIOLA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mission Pharmacal Company	THIOLA	tiopronin	0178-0900	ALUMINUM OXIDE
Mission Pharmacal Company	THIOLA	tiopronin	0178-0900	CALCIUM CARBONATE
Mission Pharmacal Company	THIOLA	tiopronin	0178-0900	CARNAUBA WAX

# THIOLA Excipient Strategy and Commercial Opportunities in Tiopronin Formulation

Last updated: August 30, 2026

THIOLA is an oral tiopronin product for preventing cystine stone formation in adults and pediatric patients weighing at least 20 kg with severe homozygous cystinuria. Its commercial value depends on chronic dosing, tablet burden, tolerability, reliable dissolution, and access to a rare-disease patient population. Excipient innovation is most attractive in delayed-release performance, swallowability, dose flexibility, taste control, stability, and manufacturing efficiency rather than in replacing tiopronin itself.

THIOLA and THIOLA EC are prescription products marketed by Travere Therapeutics. THIOLA EC is a delayed-release formulation designed to reduce gastrointestinal exposure and improve tolerability compared with immediate-release tiopronin tablets. The product is administered in divided doses and may require substantial daily tablet counts because dosing is weight-based and titrated to urinary cystine concentration [1][2].

What excipients are used in THIOLA and THIOLA EC?

Public labeling identifies conventional pharmaceutical excipients for tablet manufacture, coating, lubrication, disintegration, binding, and release control. The exact composition differs between the immediate-release and delayed-release products.

THIOLA immediate-release tablets

The immediate-release product uses standard tablet excipients associated with solid-dose manufacturing. Public product information identifies ingredients including lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium or related disintegrant systems, magnesium stearate, colloidal silicon dioxide, and coating materials, depending on strength and presentation [1].

These excipients support:

• Powder flow and die filling through colloidal silicon dioxide.
• Tablet binding through povidone.
• Mechanical strength through microcrystalline cellulose.
• Tablet breakup through croscarmellose sodium or other superdisintegrants.
• Ejection and processing through magnesium stearate.
• Product identification and protection through film coating.

The immediate-release platform is technically conventional. Its commercial defensibility comes more from the approved product, physician familiarity, rare-disease positioning, dose management, and regulatory history than from a highly differentiated excipient system.

THIOLA EC delayed-release tablets

THIOLA EC uses an enteric or delayed-release coating system intended to limit release in the stomach and permit release in the intestinal tract. The product is supplied in 100 mg and 300 mg strengths [2].

A delayed-release tiopronin formulation typically requires:

1. A chemically stable tablet core.
2. A seal coat or subcoat that limits interaction between the active ingredient and the functional coating.
3. An enteric polymer system.
4. Plasticizers and anti-tacking agents.
5. A coating process capable of delivering reproducible acid resistance and intestinal release.

The relevant excipient strategy is therefore more complex than the ingredient list alone suggests. The commercial product must control coating weight gain, film integrity, mechanical abrasion, moisture exposure, and dissolution across pH conditions.

What formulation problems does the THIOLA excipient strategy need to solve?

The main development challenge is balancing cystinuria treatment requirements with chronic oral administration.

Gastrointestinal tolerability

Tiopronin can cause gastrointestinal adverse reactions, including nausea, vomiting, abdominal pain, diarrhea, and loss of appetite [1]. A delayed-release excipient system can reduce drug contact with the gastric environment, but it does not eliminate systemic or intestinal adverse effects.

Commercial opportunity exists for formulations that improve tolerability without reducing bioavailability. Potential approaches include:

• More robust enteric coating systems.
• pH-triggered release with tighter dissolution specifications.
• Multiparticulate delayed-release capsules.
• Polymer systems that reduce rapid local drug concentration.
• Modified-release systems that smooth intestinal exposure.

Any change that materially alters release, absorption, or exposure would likely require a new drug application or a supplement with supporting comparative pharmacokinetic and clinical data.

High tablet burden

Tiopronin dosing is weight-based. The recommended initial dose is generally 20 to 30 mg/kg/day in divided doses, with titration based on urinary cystine levels and clinical response [1]. A 60 kg adult could require approximately 1,200 to 1,800 mg per day before clinical adjustment.

That dose range creates a practical burden even when 300 mg tablets are available. A formulation that improves dose density, such as a higher-strength tablet or a lower-mass tablet, could have direct commercial value.

Potential strategies include:

• A 450 mg or 600 mg tablet.
• A scored 300 mg tablet with improved dose flexibility.
• A dispersible or multiparticulate dosage form.
• A powder or granule presentation for pediatric patients.
• A combination pack organized around weight-based dosing bands.

Higher-strength tablets would require careful evaluation of dose confusion, swallowing difficulty, content uniformity, and dose titration. The opportunity is strongest if the formulation reduces daily tablet count without creating a clinically meaningful increase in adverse events.

Pediatric administration

THIOLA is indicated for pediatric patients weighing at least 20 kg, but young patients may have difficulty swallowing coated tablets. A pediatric formulation could use taste-masked granules, sprinkle capsules, an oral suspension, or dispersible tablets.

Tiopronin has a sulfur-containing chemical structure and may create odor and taste challenges. Taste masking could use:

• Polymer film coating around drug-containing granules.
• Lipid coating.
• Ion-exchange resin complexes.
• pH-dependent polymer barriers.
• Encapsulation in multiparticulate systems.

The most commercially useful pediatric product would preserve delayed release while allowing administration in a small volume of water or soft food. A liquid suspension would introduce chemical stability, sedimentation, preservative, dose-measurement, and container-closure risks. A dry granule or sprinkle formulation may offer a better balance between convenience and shelf life.

What excipient patents could protect a new THIOLA formulation?

Excipient patents would be most valuable when they claim a clinically relevant performance advantage rather than a generic list of inactive ingredients.

Enteric coating patents

A defensible patent could claim:

• A specific enteric polymer or polymer blend.
• Defined coating weight gain.
• Acid-stage resistance limits.
• Intestinal-stage release timing.
• A subcoat separating tiopronin from the enteric polymer.
• Moisture-control properties.
• A defined dissolution profile across pH 1.2, 4.5, and 6.8 conditions.

Broad claims to conventional polymers such as methacrylic acid copolymers, hypromellose phthalate, or cellulose acetate phthalate would face prior-art pressure. Narrow claims that link composition to improved stability, reduced gastric release, or improved tolerability would have greater value.

Pediatric and taste-masking patents

A taste-masking patent could cover:

• Tiopronin-loaded coated particles.
• A defined polymer-to-drug ratio.
• A specific granule size distribution.
• Release after dispersion in water or food.
• Reduced bitterness or sulfur-related odor.
• Compatibility with enteric release.

Sensory claims must be supported by reproducible testing. Commercial protection is stronger when the taste-masked product also provides a measurable pediatric administration or adherence benefit.

High-load tablet patents

High-dose formulations can generate patentable subject matter around:

• Drug loading above conventional tablet thresholds.
• Improved content uniformity.
• Reduced tablet size.
• Low friability at high active loading.
• Direct-compression or dry-granulation processes.
• Lubricant concentration and blending conditions.
• Stability under high humidity.

These claims may also protect manufacturing know-how. The strongest estate would combine composition claims, process claims, and dissolution specifications.

How does THIOLA compare with competing cystinuria therapies?

THIOLA occupies a specialized position because tiopronin directly binds cystine and forms a more soluble mixed disulfide. Other management tools include high fluid intake, urinary alkalinization, dietary measures, and older thiol drugs such as penicillamine.

Product or approach	Active treatment principle	Excipient opportunity	Commercial limitation
THIOLA immediate release	Tiopronin cystine-binding therapy	Lower-cost generic-style tablet, dose flexibility	GI tolerability and tablet burden
THIOLA EC	Delayed-release tiopronin	Enteric coating, stability, tolerability, pediatric delivery	More complex manufacturing and possible substitution barriers
D-penicillamine	Thiol-mediated cystine reduction	Taste masking, modified release, tolerability	Greater toxicity and historical use limitations
Potassium citrate or alkalinization	Raises urinary pH	Liquid, chewable, and adherence-focused formats	Does not replace cystine-binding therapy
High-fluid and dietary management	Reduces urinary cystine concentration	Convenient dosing and adherence products	Behavioral burden and incomplete control

The principal competitive threat to THIOLA is not a conventional small-molecule substitute with identical clinical positioning. It is a lower-cost tiopronin product, a formulation that improves adherence, or a therapy that reduces the need for chronic tiopronin use.

What FDA regulatory pathway applies to a new THIOLA excipient formulation?

The regulatory pathway depends on whether the product is equivalent to an approved tiopronin reference product or materially changes release and clinical performance.

Abbreviated new drug application

An ANDA may be possible for a product that matches the reference product in active ingredient, dosage form, strength, route, and performance characteristics. The applicant must address bioequivalence, inactive ingredient safety, dissolution, stability, and pharmaceutical equivalence [3].

For an immediate-release tiopronin tablet, excipient substitution is commercially feasible when the change does not alter bioavailability, release, impurity formation, or tolerability.

A delayed-release product creates more complex equivalence requirements. The applicant would need to demonstrate:

• Acid-stage resistance.
• Comparable delayed-release dissolution.
• Bioequivalence under applicable FDA standards.
• Comparable strength and dosage form.
• Acceptable inactive ingredients for the intended population.

Section 505(b)(2) application

A reformulated pediatric, sprinkle, liquid, or materially modified-release product may be better suited to a 505(b)(2) application. This route can rely in part on FDA findings for an approved tiopronin product while requiring new data for the formulation-specific differences [4].

The 505(b)(2) route may support:

• A new dosage form.
• A new strength.
• A new route or administration method.
• A delayed-release or extended-release profile.
• A pediatric presentation.
• A clinically supported tolerability improvement.

This route also creates potential for three-year regulatory exclusivity for a qualifying new clinical investigation, although the commercial value depends on the scope of the approved change and the resulting labeling.

What commercial opportunities exist for THIOLA excipients?

The most credible opportunities fall into five product categories.

1. Generic or authorized-generic immediate-release tablets

A conventional immediate-release tablet could compete on manufacturing cost, supply reliability, and payer economics. Excipient differentiation would be limited, but efficient granulation, high active loading, and robust stability could improve margins.

The main risk is price erosion. A generic entrant would also need to address the small patient population and potentially limited manufacturing scale.

2. Delayed-release competitors

A THIOLA EC-equivalent product could compete through an ANDA if reference-product requirements can be met. The technical barrier is higher because enteric coating performance and bioequivalence are more demanding than for a basic immediate-release tablet.

An entrant with a proprietary coating process may gain protection through formulation and process patents, although patent scope must be assessed against the approved product’s listed patents and prior art.

3. Pediatric sprinkle or granule products

This is the clearest unmet formulation opportunity. A pediatric product could improve administration for children who cannot swallow tablets and could create a differentiated 505(b)(2) product.

The most attractive platform is a dry, taste-masked, delayed-release granule that can be sprinkled onto a small quantity of compatible food. It would avoid the stability and dosing problems of an aqueous suspension while improving usability.

4. High-strength tablets

A 450 mg or 600 mg tablet could reduce tablet burden for adults. The product would need strong dose-selection controls and clinical usability data. A high-strength presentation may be commercially useful even if it does not qualify for automatic substitution because it could be prescribed as a new dosage form.

5. Adherence-focused packaging

Packaging is not an excipient strategy, but it can extend formulation value. A weight-based blister system could organize morning, afternoon, and evening doses. Calendar packaging, dose titration packs, and pediatric administration accessories could support adherence and reduce medication errors.

What manufacturing and intellectual-property barriers affect THIOLA opportunities?

Manufacturing barriers are moderate for immediate-release tablets and higher for delayed-release and pediatric products.

Key technical barriers include:

• Tiopronin stability during wet processing.
• Moisture sensitivity and packaging selection.
• Uniform distribution at high drug loading.
• Tablet hardness without delayed disintegration.
• Enteric coating uniformity.
• Compatibility between tiopronin and alkaline or acidic excipients.
• Odor and taste control.
• Scale-up of coating and drying processes.
• Control of dissolution after long-term storage.

The intellectual-property estate should be evaluated across four layers:

1. Product patents covering tiopronin formulations.
2. Method-of-use patents covering cystinuria treatment or dosing.
3. Manufacturing patents covering coating, granulation, or stability processes.
4. Regulatory exclusivities and listed Orange Book patents.

Excipient suppliers can participate through licensing agreements, formulation partnerships, contract development, or supply contracts. A supplier with a proprietary enteric polymer, taste-masking platform, or high-load tableting process may obtain commercial leverage without owning the drug product.

What is the likely revenue exposure and market structure?

Cystinuria is a rare inherited disorder, and treatment volume is limited by disease prevalence, diagnosis rates, pediatric treatment, and long-term adherence. The product can still support premium pricing because therapy is chronic and alternatives are limited.

Revenue exposure is concentrated in:

• Continued use of THIOLA EC.
• Reimbursement and specialty-pharmacy access.
• Patient persistence.
• Generic entry timing.
• Conversion from immediate-release to delayed-release dosing.
• New pediatric and high-strength presentations.

A lower-cost generic could expand access while reducing branded revenue. A superior pediatric or adherence product could expand treated volume and preserve premium pricing. The highest-value commercial strategy is therefore not necessarily the lowest-cost excipient formulation. It is a formulation that produces a measurable reduction in pill burden, administration difficulty, or treatment discontinuation.

What is the strongest THIOLA formulation strategy?

The strongest strategy is a differentiated delayed-release multiparticulate product with three characteristics:

• Enteric protection comparable to THIOLA EC.
• Taste and odor masking for pediatric administration.
• Dose flexibility through sachets, sprinkle capsules, or weight-based packs.

A second-best opportunity is a high-strength adult tablet supported by a lower-mass core and robust stability packaging.

A conventional immediate-release tablet has the lowest technical risk but also the weakest differentiation. Its value depends primarily on manufacturing economics and regulatory substitution.

Key Takeaways

• THIOLA contains tiopronin and is used chronically for severe cystinuria.
• THIOLA EC creates the main excipient opportunity because delayed-release performance requires a differentiated coating and stability system.
• Pediatric sprinkle granules or taste-masked delayed-release particles are the most attractive unmet formulation opportunity.
• High-strength tablets could reduce tablet burden but require careful dose-control and usability assessment.
• Conventional excipient substitution is more suitable for an ANDA; new dosage forms and modified-release products may require a 505(b)(2) application.
• Excipient patents should claim release performance, stability, taste masking, high drug loading, or manufacturing parameters rather than generic ingredient lists.
• The principal commercial risks are limited patient volume, generic entry, reimbursement pressure, and technical failure in bioequivalence or dissolution.
• A formulation that improves adherence can create more durable commercial value than a formulation that only lowers manufacturing cost.

FAQs

Can a new excipient make tiopronin easier to swallow?

Yes. Polymer-coated multiparticulates, taste-masked granules, sprinkle capsules, and dispersible dosage forms can improve administration. The formulation must preserve tiopronin stability and the intended release profile.

Could lactose be removed from a generic THIOLA formulation?

Potentially. An applicant can select alternative fillers and binders if the inactive ingredients are suitable for the dosage form and the product meets equivalence, stability, dissolution, and safety requirements.

Is a liquid THIOLA formulation commercially attractive?

It could improve pediatric administration, but aqueous tiopronin products face stability, odor, taste, preservative, sedimentation, and dosing challenges. A dry granule or sprinkle product may offer better commercial and technical economics.

Can a coating supplier patent a THIOLA-compatible enteric system?

Yes, if the claims cover a novel composition or process tied to measurable performance, such as acid resistance, intestinal release, stability, or reduced drug-excipient interaction. Broad claims to established enteric polymers are more vulnerable to prior art.

Would a 600 mg tiopronin tablet automatically replace existing THIOLA tablets?

No. A higher-strength product would require its own regulatory and labeling assessment. Substitution would depend on approval status, therapeutic equivalence, state pharmacy rules, and prescriber instructions.

References

1. U.S. Food and Drug Administration. (n.d.). THIOLA (tiopronin) tablets: Prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). THIOLA EC (tiopronin) delayed-release tablets: Prescribing information. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). U.S. Department of Health and Human Services.